Enalaprilat

• CAT Number: I026838
• CAS Number: 76420-72-9
• Molecular Formula: C18H24N2O5
• Molecular Weight: 348.39
• Purity: 98%
• Synonyms: Enalaprilat; Enalapril acid; MK 421 diacid; MK 422; MK-422; MK422
• Target: Angiotensin-converting Enzyme (ACE)
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
• IUPAC Name: (2S)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
• InChI: InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1
• InChIKey: LZFZMUMEGBBDTC-QEJZJMRPSA-N
• SMILES: C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O

Enalaprilat (Cat.No:I026838) is the active metabolite of ENALAPRIL and a potent intravenously administered angiotensin-converting enzyme inhibitor. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.

Reference

1: Ferslew BC, Köck K, Bridges AS, Brouwer KL. Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat. Drug Metab Dispos. 2014 Sep;42(9):1567-74. doi: 10.1124/dmd.114.057554. Epub 2014 Jun 23. PubMed PMID: 24958844; PubMed Central PMCID: PMC4152871.
2: Mangiacapra F, Peace AJ, Di Serafino L, Pyxaras SA, Bartunek J, Wyffels E, Heyndrickx GR, Wijns W, De Bruyne B, Barbato E. Intracoronary EnalaPrilat to Reduce MICROvascular Damage During Percutaneous Coronary Intervention (ProMicro) study. J Am Coll Cardiol. 2013 Feb 12;61(6):615-21. doi: 10.1016/j.jacc.2012.11.025. Epub 2013 Jan 2. PubMed PMID: 23290547.
3: Gómez-Díez M, Muñoz A, Caballero JM, Riber C, Castejón F, Serrano-Rodríguez JM. Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. Res Vet Sci. 2014 Aug;97(1):105-10. doi: 10.1016/j.rvsc.2014.06.006. Epub 2014 Jun 12. PubMed PMID: 24972864.
4: Burckhardt BB, Tins J, Laeer S. Simultaneous quantitative and qualitative analysis of aliskiren, enalapril and its active metabolite enalaprilat in undiluted human urine utilizing LC-ESI-MS/MS. Biomed Chromatogr. 2014 Dec;28(12):1679-91. doi: 10.1002/bmc.3201. Epub 2014 May 2. PubMed PMID: 24788577.
5: Kang YM, Zhang DM, Yu XJ, Yang Q, Qi J, Su Q, Suo YP, Yue LY, Zhu GQ, Qin DN. Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines. Toxicol Appl Pharmacol. 2014 Feb 1;274(3):436-44. doi: 10.1016/j.taap.2013.12.001. Epub 2013 Dec 14. PubMed PMID: 24342267.
6: Fujioka H, Hieda Y, Kuramoto Y, Konishi K, Kinoshita-Kikuta E, Kinoshita E, Koike T. [Increase in lipophilicity of enalaprilat by complexation with copper(II) or zinc(II) Ions]. Yakugaku Zasshi. 2013;133(10):1135-41. Epub 2013 Jul 30. Japanese. PubMed PMID: 23903258.
7: Matus M, Kucerova D, Kruzliak P, Adameova A, Doka G, Turcekova K, Kmecova J, Kyselovic J, Krenek P, Kirchhefer U, Mueller FU, Boknik P, Klimas J. Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat. Mol Cell Biochem. 2015 May;403(1-2):199-208. doi: 10.1007/s11010-015-2350-1. Epub 2015 Feb 8. PubMed PMID: 25663023.
8: Ramusovic S, Thielking G, Läer S. Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. Biomed Chromatogr. 2012 Jun;26(6):697-702. doi: 10.1002/bmc.1716. Epub 2011 Sep 23. PubMed PMID: 21953651.
9: Bi BT, Yang YB, Ma AD, Lin T, Lin HB, Yang XM, Xu JP. The effect of candesartan on the pharmacokinetics of enalaprilat in nephrotic rats. Eur Rev Med Pharmacol Sci. 2012 Dec;16(15):2162-70. PubMed PMID: 23280035.
10: Cheregi M, Albu F, Udrescu Ş, Răducanu N, Medvedovici A. Greener bioanalytical approach for LC/MS-MS assay of enalapril and enalaprilat in human plasma with total replacement of acetonitrile throughout all analytical stages. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 15;927:124-32. doi: 10.1016/j.jchromb.2012.11.023. Epub 2012 Nov 30. PubMed PMID: 23266124.
11: Cernecka H, Ochodnicka-Mackovicova K, Kucerova D, Kmecova J, Nemcekova V, Doka G, Kyselovic J, Krenek P, Ochodnicky P, Klimas J. Enalaprilat increases PPARβ/δ expression, without influence on PPARα and PPARγ, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy. Eur J Pharmacol. 2013 Aug 15;714(1-3):472-7. doi: 10.1016/j.ejphar.2013.06.040. Epub 2013 Jul 5. PubMed PMID: 23834779.
12: Loftsson T, Thorisdóttir S, Fridriksdóttir H, Stefánsson E. Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. Acta Ophthalmol. 2010 May;88(3):337-41. doi: 10.1111/j.1755-3768.2008.01495.x. Epub 2009 Apr 29. PubMed PMID: 19432862.
13: Bautista-Pérez R, Arellano A, Franco M, Osorio H, Coronel I. Enalaprilat-mediated activation of kinin b(1) receptors and vasodilation in the rat isolated perfused kidney. Pharmacology. 2011;87(3-4):195-203. doi: 10.1159/000324513. Epub 2011 Mar 25. PubMed PMID: 21430409.
14: Murphy JD, Vaughan RS, Rosen M. Intravenous enalaprilat and autonomic reflexes. The effects of enalaprilat on the cardiovascular responses to postural changes and tracheal intubation. Anaesthesia. 1989 Oct;44(10):816-21. PubMed PMID: 2556057.
15: Persson IA. The pharmacological mechanism of angiotensin-converting enzyme inhibition by green tea, Rooibos and enalaprilat – a study on enzyme kinetics. Phytother Res. 2012 Apr;26(4):517-21. doi: 10.1002/ptr.3588. Epub 2011 Sep 8. PubMed PMID: 22095883.
16: Salgado DR, He X, Su F, de Sousa DB, Penaccini L, Maciel LK, Taccone F, Rocco JR, Silva E, De Backer D, Vincent JL. Sublingual microcirculatory effects of enalaprilat in an ovine model of septic shock. Shock. 2011 Jun;35(6):542-9. doi: 10.1097/SHK.0b013e3182115e6a. PubMed PMID: 21283060.
17: Pang KS, Cherry WF, Terrell JA, Ulm EH. Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. Drug Metab Dispos. 1984 May-Jun;12(3):309-13. PubMed PMID: 6145558.
18: Rutledge J, Ayers C, Davidson R, DiPette D, Guthrie G, Fisher M, Schwartz S, Rucinska E. Effect of intravenous enalaprilat in moderate and severe systemic hypertension. Am J Cardiol. 1988 Nov 15;62(16):1062-7. PubMed PMID: 2847522.
19: Tohmo H, Karanko M, Korpilahti K. Haemodynamic effects of enalaprilat and preload in acute severe heart failure complicating myocardial infarction. Eur Heart J. 1994 Apr;15(4):523-7. PubMed PMID: 8070480.
20: Tarkiainen EK, Tornio A, Holmberg MT, Launiainen T, Neuvonen PJ, Backman JT, Niemi M. Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol. 2015 Nov;80(5):1131-8. doi: 10.1111/bcp.12667. Epub 2015 Jun 11. PubMed PMID: 25919042; PubMed Central PMCID: PMC4631185.